15850 Visiopharm announces Christian Kaltoft as Chief Operating Officer

Visiopharm is pleased to announce the appointment of Christian Kaltoft as Chief Operating Officer (COO).

Christian joins with over 15 years of experience in the pharma and life science industry. For the last eight years Christian has worked at Agilent Technologies in a variety of leadership positions within Agilent’s cancer diagnostic division. Agilent is a leading company within tissue-based cancer diagnostic and companion diagnostic. Most recently he was director of diagnostic hardware and software portfolio within global pathology marketing.

Before Agilent, Christian held positions in pharma within medical, sales and marketing, which provides Christian with a deep understanding of both the pharma, diagnostic and critical interface that enables precision medicine.

Christian takes over from current COO Thomas Ahl who will retire in the new year. Thomas has been at Visiopharm since February 2018, during which time he contributed heavily to the transformation of Visiopharm into a global and scalable business. “Thomas has been instrumental in transforming Visiopharm into a truly scalable enterprise with global presence, and we are very grateful to him for his role in this critical part of our journey,” said Michael Grunkin, CEO of Visiopharm.

Visiopharm CEO, Michael Grunkin said:

“We are very pleased that Christian is joining us at a time where we are embarking on this next exciting phase of our journey towards becoming a global tissue-diagnostic company. He is bringing a deep understanding of the market needs, where in the tissue diagnostic workflows AI can move the needle on productivity and precision, and from a cross-functional perspective, how Visiopharm can most efficiently deliver on all those parameters.”

Christian Kaltoft said:

“I’m excited to be joining Visiopharm at such a pivotal time. I have evaluated the digital pathology market and the continuous evolution. Visiopharm are one of very few AI companies in the pathology space with a proven commercial track record in the diagnostic market with a footprint of 75 diagnostic pathology labs throughout many countries. I believe that Visiopharm is very well-positioned to lead the next evolution that will enable improved standardization and expand clinical utility of image analysis in routine diagnostic setting.”

Categories: Press Releases 15888 Fluidigm and Visiopharm announce co-marketing programme

Fluidigm Corporation and Visiopharm today announced a new co-marketing programme, to offer Visiopharm® image analysis software for faster and more streamlined analysis of data acquired through Imaging Mass Cytometry™ (IMC™). The programme is the latest phase of an ongoing collaboration between the two companies.

Visiopharm is a world leader in image analysis, with a mission to transform pathology through AI-based image analysis and workflow standardization, offering solutions for digital pathology.

New software developed in collaboration with Visiopharm will enable native reading of data files from the Hyperion™ Imaging System, which uses IMC technology, imported into Visiopharm analysis tools. The new software will be launched at the 2021 Fluidigm IMC Summit on 21 October.

“As part of this latest milestone in our collaboration with Fluidigm, Visiopharm becomes the first company to provide third-party software that enables native reading of Imaging Mass Cytometry data files, with all metadata and imagery intact, eliminating the need for conversion to an intermediate format,” said Visiopharm CTO Johan Doré Hansen. “This simplifies the workflow, enabling faster analysis of cellular phenotypes and their interrelationships within the spatial context of the tissue microenvironment.

“With advanced capabilities for high-plex analysis and subsequent data mining, we believe Visiopharm is the partner of choice for the analysis of Imaging Mass Cytometry data files, and this enhancement will be yet another reason for researchers to choose IMC as the premier tool for uncovering meaningful new insights in health and disease.”

Globally, mass cytometry is utilized by 9 of the top 10 pharma companies. Mass cytometry technologies, including CyTOF®, Imaging Mass Cytometry and Maxpar® Direct™, have been used in more than 160 National Clinical Trials.

“The translational and clinical research testing markets have come to rely upon the Hyperion Imaging System for imaging solutions for biomarker discovery and drug development,” said Chris Linthwaite, President and CEO. “We are excited to partner with Visiopharm to further expand the ecosystem of Imaging Mass Cytometry data analysis tools, which provide valuable insights and advance health care decision making.”

About Visiopharm

Visiopharm® is a world leader in AI-driven digital pathology solutions. Visiopharm’s pioneering image analysis tools support thousands of scientists, pathologists, and image analysis experts in both academic institutions and the biopharmaceutical industry.

AI-based image analysis and tissue mining tools support research and drug development research worldwide, while their CE-IVD APPs support diagnostics. With the most advanced and sophisticated artificial intelligence and deep learning, they deliver tissue data mining tools, precision results, and workflows. Visiopharm was founded in 2001 and is privately owned. The company operates internationally with over 900 licenses and countless users in more than 40 countries. Company headquarters are in Denmark’s Medicon Valley, with further offices in Sweden, United Kingdom, Germany, Netherlands, and the United States.

About Fluidigm

Fluidigm (Nasdaq:FLDM) focuses on the most pressing needs in translational and clinical research, including cancer, immunology, and immunotherapy. Using proprietary CyTOF and microfluidics technologies, we develop, manufacture, and market multi-omic solutions to drive meaningful insights in health and disease, identify biomarkers to inform decisions, and accelerate the development of more effective therapies. Our customers are leading academic, government, pharmaceutical, biotechnology, plant and animal research, and clinical laboratories worldwide. Together with them, we strive to increase the quality of life for all. For more information, visit fluidigm.com.

Fluidigm, the Fluidigm logo, CyTOF, Hyperion, Imaging Mass Cytometry, IMC, and Maxpar are trademarks and/or registered trademarks of Fluidigm Corporation or its affiliates in the United States and/or other countries. All other trademarks are the sole property of their respective owners. Fluidigm products are provided for Research Use Only. Not for use in diagnostic procedures.

Categories: Press Releases
Your message has been successfully sent!